T he Universal Definition of Myocardial Infarction (UDMI) 1 classifies myocardial infarction (MI) into 5 subtypes, of which type 1 and type 2 MI are the most common and relevant to practicing clinicians. Type 1 MI is defined as MI caused by acute atherothrombotic mechanisms, with type 2 MI defined as MI resulting from myocardial oxygen supply/demand mismatch without acute atherothrombosis. The UDMI recognizes multiple potential causes of type 2 MI, including demand-side abnormalities such as tachyarrhythmia or severe hypertension, and supply-side issues such as severe anemia, hypoxemia, or hypotension. Type 2 MI may occur with or without obstructive coronary disease, with the threshold for type 2 MI lower in patients with fixed obstructive coronary artery disease.
and treatment responses of type 2 MI, as currently defined, is of little value other than making sure that these diagnoses do not muddy the interpretation of type 1 MI. However, including patients without acute atherothrombosis in the type 1 MI category also creates problems. Clinical trials and guideline recommendations for management of acute coronary syndromes are only applicable to type 1 MI. For example, applying therapies tested in atherothrombosis, such as parenteral anticoagulation and intracoronary stenting, to patients with SCAD may be harmful. 4 Evidenced-based therapies exist for coronary vasospasm and are emerging for SCAD, with coronary embolism typically managed empirically based on the source of embolism. However, such therapies are clearly distinct from those used to treat acute atherothrombosis.
We propose consideration of a modest redefinition of type 1 and type 2 MI (Figure) , with type 1 MI defined by acute coronary obstruction or reduction in coronary blood flow rather than by atherothrombosis. This would move SCAD, coronary embolism, and coronary vasomotor abnormalities (including epicardial vasospasm and microvascular dysfunction) into the type 1 MI category. We further propose subclassifying type 1 MI based on the underlying pathophysiology, with type 1A MI being the typical atherothrombosis category and the other etiologies having separate subclassifications ( Figure) . Type 2 MI would be defined as MI attributable to acute supply/demand mismatch without acute coronary obstruction. We propose further subclassifying type 2 MI into those with or without obstructive coronary artery disease (Figure) , because the subsequent management approaches differ substantially based on the presence of severe coronary artery disease. As an important corollary, modification of International Classification of Diseases (ICD) codes to improve specificity would be an important step forward for research and quality improvement in patients with MI caused by factors other than atherothrombosis.
We believe that this redefinition would better align with modern approaches to diagnosis and management of the spectrum of patients with MI. It would facilitate research into specific diagnostic subcategories and identification of optimal treatment approaches. This designation would also eliminate the need for a separate classification scheme for myocardial infarction with no obstructive coronary disease. 5 Each of the categories of myocardial infarction with no obstructive coronary disease would fit within the new MI definition construct. Also, the creation of subcategories (type 1A, 1B, etc) would allow room for additional MI phenotypes, as new information on pathophysiology becomes available, without altering the fundamental structure of the classification.
Although some may view differences between the Universal Definition of Myocardial Infarction and our proposed revision as little more than administrative details, we would argue that alignment of diagnosis with clinical presentation, pathophysiology, and diagnostic approach is an essential step to address current knowledge gaps. Moreover, accurate diagnosis has direct implications for quality reporting, because evidence-based standards exist only for MI attributable to atherothrombosis. Clinicians should be held accountable only for adhering to process and performance measures for those patients in whom the measures apply. Finally, and
